Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 11,330 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Cohorting Clear all
Completed Phase 4 Interventional Results available

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

NCT04566692
View directory record Official record
Conditions
Primary Immunodeficiency
Interventions
IGSC 20%
Biological
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
6 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
12
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • North Palm Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational

Spatial Neglect and Delirium After Stroke

NCT03349411
View directory record Official record
Conditions
Stroke, Delirium, Spatial Neglect
Interventions
Confusion Assessment Method, Behavioral Inattention Test, Magnetic Resonance Imaging, Florida Mental Status Examination, Montreal Cognitive Assessment, Geriatric Depression Scale, Kessler Foundation Neglect Assessment Process
Diagnostic Test
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 100 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
West Orange, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients

NCT01702064
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Nilotinib, Ruxolitinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 20, 2026, 5:33 AM EDT
Recruiting No phase listed Observational

Precision-Based Genomics in Prostate Cancer

NCT04706663
View directory record Official record
Conditions
Prostate Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
11
States / cities
La Jolla, California • San Francisco, California • Evanston, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Hybrid Closed-Loop Hotel Studies With Medtronic PID Controller

NCT02280863
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic Hybrid Closed-loop System - Android Platform, Medtronic Hybrid Closed-loop Integrated System
Device
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 3, 2018 · Synced Oct 20, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional

Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma

NCT01123304
View directory record Official record
Conditions
Melanoma
Interventions
MORAb028
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational

Role and Mechanisms of Lipid and Lipoprotein Dysregulation in Sepsis

NCT04576819
View directory record Official record
Conditions
Sepsis, Shock, Septic
Interventions
Not listed
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 1Phase 2 Interventional Results available

LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma

NCT03773107
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Carfilzomib, Ruxolitinib, Dexamethasone
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Detroit, Michigan • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety of Escalating Doses of DLYE5953A in Patients With Refractory Solid Tumors

NCT02092792
View directory record Official record
Conditions
Neoplasms
Interventions
DLYE5953A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
5
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational

Incidence of Second Primary Malignancies in Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the US

NCT02788409
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not applicable for study
Other
Lead sponsor
Bayer
Industry
Eligibility
65 Years and older · Male only
Enrollment
2,234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen

NCT03974932
View directory record Official record
Conditions
Analgesia
Interventions
HTX-011, Ibuprofen, Acetaminophen, Celecoxib, +/- Bupivacaine HCl, Luer Lock Applicator
Drug · Device
Lead sponsor
Heron Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
6
States / cities
Sheffield, Alabama • Tamarac, Florida • Dayton, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4, Open-label Study of KRYSTEXXA® (Pegloticase) Co-administered With Methotrexate (MTX) in Patients With Uncontrolled Gout (FORWARD OL)

NCT04762498
View directory record Official record
Conditions
Uncontrolled Gout, Chronic Gout
Interventions
Pegloticase, Methotrexate (MTX)
Biological · Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
12
States / cities
Anchorage, Alaska • Glendale, Arizona • San Leandro, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational

Study to Explore Natural Daily Variation and Impact of Stress in HIV Levels

NCT02895087
View directory record Official record
Conditions
HIV
Interventions
Diurnal Variation Group, External Stress Group
Other
Lead sponsor
University of Melbourne
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
San Francisco, California • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:33 AM EDT
Active, not recruiting No phase listed Observational

Multicenter Symphony™ IL-6 Monitoring Sepsis ED Pilot Study

NCT07425587
View directory record Official record
Conditions
Sepsis, Septic Shock
Interventions
Not listed
Lead sponsor
Bluejay Diagnostics, Inc.
Industry
Eligibility
22 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Gainesville, Florida • Boston, Massachusetts • Winston-Salem, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Terminated No phase listed Observational

A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer

NCT05780736
View directory record Official record
Conditions
Esophageal Carcinoma, Gastroesophageal Junction Carcinoma
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
11
States / cities
Birmingham, Alabama • San Luis Obispo, California • Santa Maria, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 20, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 20, 2026, 5:33 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells

NCT03107416
View directory record Official record
Conditions
Unresectable Hepatocellular Carcinoma
Interventions
Hepatic artery embolization (HAE), Bumetanide
Procedure · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Recruiting No phase listed Observational

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

NCT06600906
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma
Interventions
Hyperpolarized 13C-Pyruvate, Computed tomography (CT), Magnetic Resonance Imaging (MRI)
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

NCT03902184
View directory record Official record
Conditions
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
Interventions
IPH4102
Biological
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 5:33 AM EDT
Enrolling by invitation No phase listed Observational

Exactech Knee Systems Post Market Clinical Follow-up

NCT07107581
View directory record Official record
Conditions
Knee Arthroplasty, Total, Partial Knee Replacement
Interventions
Prospective / Subjects Knee Arthroplasty, Retrospective to Prospective, Retrospective Only Subjects
Device
Lead sponsor
Exactech
Industry
Eligibility
18 Years and older
Enrollment
1,879 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
1
States / cities
DeLand, Florida
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Results available

A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer.

NCT03840200
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Ovarian Cancer
Interventions
Ipatasertib, Rucaparib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
San Marcos, California • East Brunswick, New Jersey • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 20, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Assessing Neuroinflammation in GWI Using MRS

NCT04638998
View directory record Official record
Conditions
Gulf War Syndrome
Interventions
Magnetic Resonance Spectroscopic Imaging, Blood draw
Procedure
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
46 Years to 70 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Oct 20, 2026, 5:33 AM EDT
Completed No phase listed Observational

West Nile Virus Natural History

NCT00138463
View directory record Official record
Conditions
West Nile Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 20, 2026, 5:33 AM EDT